News | November 24, 2025
Moderna bags $1.5 billion 5-Yr loan to boost financial flexibility
The non-dilutive financing includes three tranches
The non-dilutive financing includes three tranches
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Subscribe To Our Newsletter & Stay Updated
